Ultragenyx (NASDAQ:RARE) — Stock Price
Ultragenyx (NASDAQ:RARE) is currently trading at $26.80 USD, up 3.43% today. Over the past 52 weeks, shares have ranged between $18.50 and $36.54. This page tracks Ultragenyx's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Ultragenyx worth.
Ultragenyx (RARE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ultragenyx's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Ultragenyx Income Statement — Revenue, Profit & Earnings by Year
Ultragenyx's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $673.00 Million | $560.23 Million | $434.25 Million | $363.33 Million | $351.41 Million |
| Cost of Revenue | $109.00 Million | $76.73 Million | $45.21 Million | $28.32 Million | $16.01 Million |
| Gross Profit | $564.00 Million | $483.50 Million | $389.04 Million | $335.01 Million | $335.40 Million |
| Research & Development | $750.00 Million | $697.87 Million | $648.45 Million | $705.79 Million | $497.15 Million |
| SG&A | $349.00 Million | $321.61 Million | $309.80 Million | $278.14 Million | $219.98 Million |
| Total Operating Expenses | $1.10 Billion | $1.02 Billion | $958.25 Million | $983.93 Million | $717.13 Million |
| Operating Income | $-535.00 Million | $-535.97 Million | $-569.21 Million | $-648.92 Million | $-381.74 Million |
| EBITDA | $-500.00 Million | $-469.00 Million | $-516.45 Million | $-640.49 Million | $-410.32 Million |
| EBIT | $-535.00 Million | $-504.55 Million | $-542.46 Million | $-658.71 Million | $-423.56 Million |
| Interest Expense | $62.00 Million | $63.04 Million | $66.00 Million | $43.02 Million | $29.42 Million |
| Income Before Tax | $-571.00 Million | $-567.59 Million | $-608.46 Million | $-701.73 Million | $-452.98 Million |
| Income Tax Expense | $4.00 Million | $1.60 Million | $-1.82 Million | $5.70 Million | $1.04 Million |
| Net Income | $-575.00 Million | $-569.18 Million | $-606.64 Million | $-707.42 Million | $-454.02 Million |
Ultragenyx Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ultragenyx's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $1.53 Billion | $1.50 Billion | $1.49 Billion | $1.55 Billion | $1.52 Billion |
| Total Current Assets | $951.00 Million | $817.12 Million | $732.18 Million | $883.90 Million | $856.60 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $259.00 Million | $436.30 Million | $363.62 Million | $614.82 Million | $432.61 Million |
| Net Receivables | $159.00 Million | $121.80 Million | $73.39 Million | $40.45 Million | $28.43 Million |
| Inventory | $52.00 Million | $45.01 Million | $33.97 Million | $26.77 Million | $16.23 Million |
| Property, Plant & Equipment | — | — | — | $259.73 Million | $141.25 Million |
| Goodwill | $44.00 Million | $44.41 Million | $44.41 Million | $44.41 Million | $44.41 Million |
| Total Liabilities | $1.60 Billion | $1.24 Billion | $1.22 Billion | $1.19 Billion | $599.84 Million |
| Total Current Liabilities | $384.00 Million | $344.15 Million | $280.44 Million | $261.21 Million | $181.37 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $842.00 Million | $-133.39 Million | $-170.41 Million | $-101.35 Million | $-265.61 Million |
| Total Stockholder Equity | $-80.00 Million | $255.30 Million | $275.41 Million | $352.49 Million | $922.56 Million |
| Retained Earnings | $-4.53 Billion | $-3.96 Billion | $-3.39 Billion | $-2.78 Billion | $-2.07 Billion |
Ultragenyx Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ultragenyx generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-466.00 Million | $-414.19 Million | $-474.81 Million | $-380.46 Million | $-338.69 Million |
| Capital Expenditures | $6.00 Million | $7.49 Million | $46.77 Million | $146.12 Million | $73.09 Million |
| Free Cash Flow | $-472.00 Million | $-421.68 Million | $-521.57 Million | $-526.59 Million | $-411.79 Million |
| Investing Cash Flow | $236.00 Million | $-17.77 Million | $168.00 Million | $-291.65 Million | $-195.37 Million |
| Financing Cash Flow | $478.00 Million | $399.24 Million | $388.14 Million | $501.21 Million | $118.55 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $153.00 Million | $158.03 Million | $135.21 Million | $130.38 Million | $104.95 Million |
| Depreciation | $35.00 Million | $35.54 Million | $26.01 Million | $18.22 Million | $13.24 Million |
| Change in Cash | $253.47 Million | $-35.24 Million | $81.80 Million | $-171.98 Million | $-416.71 Million |
Ultragenyx Earnings History — EPS Actual vs. Analyst Estimates
Track Ultragenyx's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -1.54 | -1.34 | -14.99% |
| Feb 12, 2026 | -1.29 | -1.15 | -12.17% |
| Nov 06, 2025 | -1.81 | -1.21 | -49.59% |
| Aug 05, 2025 | -1.17 | -1.32 | +11.36% |
| May 06, 2025 | -1.57 | -1.64 | +4.27% |
| Feb 13, 2025 | -1.39 | -1.27 | -9.45% |
| Nov 05, 2024 | -1.40 | -1.47 | +4.76% |
| Aug 01, 2024 | -1.52 | -1.69 | +10.06% |